Sycamore Entertainment Group (OTCMKTS:SEGI) and Bicycle Therapeutics (NASDAQ:BCYC) Head to Head Review

Sycamore Entertainment Group (OTCMKTS:SEGI) and Bicycle Therapeutics (NASDAQ:BCYC) are both consumer discretionary companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Institutional and Insider Ownership

86.2% of Bicycle Therapeutics shares are owned by institutional investors. 75.5% of Sycamore Entertainment Group shares are owned by company insiders. Comparatively, 8.5% of Bicycle Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Sycamore Entertainment Group and Bicycle Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sycamore Entertainment Group	N/A	N/A	N/A
Bicycle Therapeutics	-450.64%	-27.35%	-20.81%

Risk and Volatility

Sycamore Entertainment Group has a beta of 48.79, indicating that its stock price is 4,779% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Valuation & Earnings

This table compares Sycamore Entertainment Group and Bicycle Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sycamore Entertainment Group	N/A	N/A	N/A	N/A	N/A
Bicycle Therapeutics	$26.98 million	34.78	-$180.66 million	($3.29)	-4.13

Sycamore Entertainment Group has higher earnings, but lower revenue than Bicycle Therapeutics.

Analyst Recommendations

This is a summary of recent recommendations for Sycamore Entertainment Group and Bicycle Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sycamore Entertainment Group	0	0	0	0	0.00
Bicycle Therapeutics	0	2	7	0	2.78

Bicycle Therapeutics has a consensus target price of $34.50, suggesting a potential upside of 153.86%. Given Bicycle Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Bicycle Therapeutics is more favorable than Sycamore Entertainment Group.

About Sycamore Entertainment Group

Sycamore Entertainment Group, Inc., a diversified entertainment company, which specializes in the acquisition, marketing, and worldwide distribution of feature-length motion pictures. The company is based in Seattle, Washington.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.